European Commission Approves MSD's Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma
July 22, 2015 at 07:00 AM EDT
MSD, known as Merck in the United States and Canada, today announced that the European Commission has approved KEYTRUDA® ...
